INVO Bioscience to Report Fourth Quarter and Fiscal Year 2020 Financial Results on Tuesday, March 30, 2021

Mar 26, 2021 | Press Releases

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ETSARASOTA, Fla., March 26, 2021 — INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo...

INVO Bioscience Achieves Key Milestone – Signs Agreement to Open First Joint Venture INVOcell Clinic in the United States

Mar 15, 2021 | Press Releases

INVO has partnered with experienced reproductive specialists who are strong advocates of the INVOcell solutionClinic to be located in Birmingham, Alabama with a focus on providing INVOcell as an efficient, effective and affordable fertility treatment option for the...

INVO Bioscience to Participate in the 33rd Annual Roth Conference

Mar 11, 2021 | Press Releases

SARASOTA, Fla., March 11, 2021 – INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients...

INVO Bioscience Expands Company-Owned Clinic Opportunity Under Amended U.S. Commercialization Agreement

Mar 8, 2021 | Press Releases

SARASOTA, Fla., March 8, 2021 – INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients...

INVO Bioscience Obtains Regulatory Approval to Import INVOcell Into Mexico

Mar 1, 2021 | Press Releases

SARASOTA, Fla., March 1, 2021 — INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients...